EU CLP Regulation Harmonised Classification and Labelling (CLH: Annex VI) System and ATP Amendment Process
ENFORCEMENT TIMELINE
In force since January 20, 2009 (updated annually through Adaptations to Technical Progress)
Overview
This card focuses on the legal process and amendment practice for the EU's Harmonised Classification and Labelling (CLH) system, established under Article 37 and Annex VI of the CLP Regulation (Regulation (EC) No 1272/2008).
The CLH system is a centralized mechanism designed to prevent inconsistent self-classification across companies for substances with particularly severe hazards — such as CMR substances (carcinogenic, mutagenic, or toxic for reproduction) and respiratory sensitizers — by legally mandating a single, EU-wide hazard classification and label. A Member State authority or a chemical manufacturer or importer submits a CLH proposal (an intention notice and assessment dossier) to ECHA; following scientific evaluation by ECHA's Committee for Risk Assessment (RAC) and public consultation, the European Commission adopts the classification as an Adaptation to Technical Progress (ATP), publishing it in the Official Journal as a binding legal requirement.
Enforcement Timeline
Registry of Intention (ROI): A Member State authority or company submits and publishes its intention to propose a harmonised classification to ECHA.
RAC opinion (within 18 months): Following public comment, ECHA's Committee for Risk Assessment (RAC) adopts its scientific opinion.
Commission adoption and ATP publication: The European Commission publishes the classification in the EU Official Journal as an ATP, after the European Parliament and Council's objection period.
Mandatory application (approximately 18 months after publication): Following ATP publication, suppliers worldwide must comply with the new harmonised classification and update labels accordingly.
Business Impact
Where a substance a company manufactures or uses is added to, or reclassified under, the EU's harmonised classification list (Annex VI of the CLP Regulation) — for example, being assigned to carcinogenicity Category 1A or 1B — the company must update its SDS, GHS labelling, and hazard classification in line with the legally mandated classification by the ATP's application date, regardless of its own prior self-classification. A CMR designation under CLH flows through immediately to REACH authorization (Annex XIV) and restriction (Annex XVII) requirements, and can trigger outright prohibition under regulations such as those governing cosmetics and toys, posing a direct risk to business continuity.
Chemical and materials companies should therefore continuously monitor ECHA's Registry of CLH intentions and, where their own substances are under RAC review, proactively submit scientific data — including counter-evidence and safety data — during the consultation period as part of a broader legal and regulatory strategy.